Despite strong revenue growth, the company's P/S ratio remai...
Despite strong revenue growth, the company's P/S ratio remains lower than industry peers, indicating investor skepticism about sustained growth. The recent share price surge didn't align the P/S ratio with the industry median, hinting at potential risks pressuring the share price.
Investors Still Aren't Entirely Convinced By Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd's (SZSE:301126) Revenues Despite 28% Price Jump
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment